Endonovo Therapeutics, Inc. balance sheet ENDV

Annual Quarterly

As of Sep 30, 2023, Endonovo Therapeutics, Inc. had total assets of $815,764 and total liabilities of $23.8 million. Total assets were down 43.8% from a year earlier. Stockholders' equity was negative, at -$23.0 million, because liabilities exceed assets. It held $0 in cash and investments against $7.1 million of total debt, net debt of $7.1 million. The current ratio, current assets divided by current liabilities, was 0.00.

USD in millions, except ratios and per-share amounts. The percent under a figure is the change from the same quarter a year earlier.

Q3 FY2023
Sep 30, 2023
Q2 FY2023
Jun 30, 2023
Q1 FY2023
Mar 31, 2023
Q4 FY2022
Dec 31, 2022
Q3 FY2022
Sep 30, 2022
Q2 FY2022
Jun 30, 2022
Q1 FY2022
Mar 31, 2022
Q4 FY2021
Dec 31, 2021
Assets
Cash
0
-100.0%
0
-62.1%
0
-81.8%
—
0
+303.7%
—
0
-30.2%
0
+540.4%
Cash and investments
0
-100.0%
0
-62.1%
0
-81.8%
—
0
+303.7%
—
0
-30.2%
0
+540.4%
Receivables
—
—
0
+230.2%
—
0
-86.7%
0
-90.0%
0
-87.4%
0
+0.2%
Total current assets
0
+47.4%
0
+1125.1%
0
+47.7%
0
-83.3%
0
-61.5%
0
-84.6%
0
-48.1%
0
+105.4%
Total assets
1
-43.8%
1
-36.4%
1
-33.9%
1
-36.2%
1
-32.1%
2
-29.9%
2
-28.0%
2
-23.0%
Liabilities and equity
Accounts payable
—
—
—
1
+34.3%
1
+15.0%
1
+10.5%
1
-2.5%
1
-6.1%
Total current liabilities
24
+13.0%
23
+11.9%
25
+28.9%
33
+88.6%
21
+3.5%
21
+7.8%
20
+7.8%
18
+5.2%
Total liabilities
24
+12.9%
23
+11.9%
26
+28.8%
33
+88.2%
21
+3.4%
21
+7.8%
20
+7.3%
18
+4.7%
Stockholders' equity
-23
-17.1%
-22
-17.0%
-24
-35.1%
-32
-104.0%
-20
-7.6%
-19
-12.8%
-18
-12.9%
-16
-9.7%
Debt
Long-term debt
7
-2.5%
7
-4.8%
7
-6.2%
7
-1.4%
7
+6.6%
7
+10.1%
7
+7.6%
7
+6.2%
Total debt
7
-2.5%
7
-4.8%
7
-6.2%
7
-1.4%
7
+6.6%
7
+10.1%
7
+7.6%
7
+6.2%
Net cash
-7
+2.2%
-7
+4.1%
-7
+5.5%
—
-7
-6.3%
—
-7
-8.0%
-7
-5.1%
Ratios
Current ratio
0.00x
0.00x
0.00x
0.00x
0.00x
0.00x
0.00x
0.01x
Return on assets
-539.88%
-417.94%
-736.61%
-1,441.92%
-216.80%
-254.99%
-156.32%
-154.69%
Book value per share
-0.07
-0.08
-0.09
-0.15
-0.12
-0.13
-0.22
-0.21
How these figures are calculated

Quarterly columns are single-quarter amounts. When a 10-Q reports only a year-to-date total, as cash flow statements do, the quarter is that total minus the previous quarter's year-to-date total. The fourth quarter is the annual report's full year minus the first nine months. A column marked YTD is a year-to-date total, shown when the earlier report needed for the single quarter is missing. USD in millions, except ratios and per-share amounts. Cash and investments adds short-term and long-term marketable securities to cash. Debt due within a year is the borrowings that are not already in long-term debt. Total debt is those borrowings plus lease liabilities. Net cash is cash and investments minus total debt. Return on equity and return on assets divide the trailing twelve months of net income by the balance on that date. Debt to EBITDA uses the trailing twelve months of EBITDA. More on our methodology.

Company profile

Industry
Electromedical & Electrotherapeutic Apparatus (SIC 3845)
Listed as
ENDV (OTC)
Fiscal year ends
December 31
Incorporated in
DE
Headquarters
Woodland Hills, CA
SEC filer status
Non-accelerated filer, Smaller reporting company
SEC CIK
1528172
Former names
Hanover Portfolio Acquisitions, Inc. (until Jan 24, 2014)

Other Electromedical & Electrotherapeutic Apparatus companies

All 31 Electromedical & Electrotherapeutic Apparatus companies

Source: SEC EDGAR filings. This is company-reported data, not investment advice.